Study A - MK0767 Monotherapy Study

Phase 3

Terminated

• Conditions: Diabetes Mellitus, Type 2

• Registration Number: NCT00543517
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

The purpose of this study is to test if MK0767 lowers blood glucose after 20 weeks compared to placebo.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design

Study Timeline

• Study Start: 2003-02
• Primary Completion: 2003-11
• Study Completion: 2003-11
• Study First Submitted: 2007-10-05
• Study First Submitted QC: 2007-10-12
• Study First Posted: 2007-10-15
• Status Verified: 2015-02
• Last Update Submitted: 2015-02-09
• Last Update Posted: 2015-02-10

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 99

Inclusion Criteria

• Patients with Type 2 Diabetes
• Non-pregnant females and patients who agree not to become pregnant during the study

Read More

Exclusion Criteria

• Patients with Type 1 Diabetes
• Patients who have been treated with insulin or other antihyperglycemic agents
• Patients with viral hepatitis, active liver or gallbladder disease, history of pancreatitis, heart disease, congestive heart failure, inadequately controlled hypertension, HIV positive, history hematologic disorders or neoplastic disease

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL